Impact of Genetic Variants on Failure of Active Surveillance for ProstateCancer

Dr. Kundu will accrue 217 patients for active surveillance from all active surveillance sites in the Chicago SPORE. Staff will perform semi-annual serum PSA testing, digital rectal exams and obtain blood and urine for analysis of additional biomarkers every 6 months. Blood samples will be genotyed at deCODE genetics. Dr. Kundu will provide the analyzed data regarding using single nucleotide polymorhpisms (SNPs) to predict the likelihood of active surveillance failure to Northshore. Study data will be pooled from Northwestern and Northshore to provide in a prospective manner, whether a panel of SNPs can be used to guide patients towards active surveillance or definitive treatment.